FDA Committee Recommended 2027 Southern Hemisphere Flu Strains
The advisory group approved H1N1, H3N2, and influenza B strains for the upcoming 2027 seasonal vaccine.
Updated on Oct. 1, 2026 in Allergies
Live Poll
Do you trust the federal government's process for selecting annual flu vaccine strains?
The FDA's Vaccines and Related Biological Products Advisory Committee has recommended specific virus strains for the 2027 Southern Hemisphere influenza vaccine. All nine voting members reached a consensus on the inclusion of H1N1, H3N2, and influenza B strains.
Why it matters
The committee's recommendation helps guide vaccine composition by ensuring manufacturers target the most prevalent strains. These non-binding suggestions are based on assessments from the recent Northern Hemisphere flu season, during which few changes in virus circulation were detected.
The committee reached a unanimous recommendation with all nine voting members supporting the selection. Officials are currently planning for up to 135 million flu vaccine doses to be produced for the U.S. market during the 2026-2027 season.
The players
Vaccines and Related Biological Products Advisory Committee
This FDA advisory group provides non-binding recommendations on the safety, purity, and potency of vaccines.
Food and Drug Administration
The federal agency is responsible for protecting public health by ensuring the safety and efficacy of medical products.
Centers for Disease Control and Prevention
This national public health agency tracks disease prevalence and provides data on seasonal illness burdens.
The details
The committee evaluated data from the Northern Hemisphere to select strains that reflect the current influenza landscape. This process aims to maintain vaccine efficacy by aligning the composition with the most active virus variants observed globally.
Timeline
September 18, 2026: The reported date for laboratory-confirmed influenza hospitalizations data.
October 1, 2026: The date the committee recommended the 2027 Southern Hemisphere vaccine strains.
2027: The period for the Southern Hemisphere influenza season.
The Big Picture
This recommendation follows a recent U.S. influenza season that saw between 32 million and 57 million illnesses. The committee's selection process is anchored by observations from the 2025-26 U.S. influenza season illness estimates to ensure broad coverage.
These vaccine selections help ensure that future flu shots remain effective against circulating virus strains. Most individuals will see the results of this work when updated seasonal vaccines become available for their routine annual immunization visits.
The takeaway
Maintaining up-to-date vaccine compositions is essential for mitigating the impact of influenza during high-transmission months. Readers should consult their healthcare providers as the next flu season approaches to ensure they receive the latest protection.
Further reading
Learn more about seasonal health guidance on the United States Allergies page.
Live Poll
Do you trust the federal government's process for selecting annual flu vaccine strains?
